NFE2L2 (NFE2 like bZIP transcription factor 2; HGNC:7782, NCBI Gene ID 4780) is a human locus mapped to chromosome band 2q31.2 that encodes cap-n-collar basic leucine zipper (CNC-bZIP) transcription factor NRF2 (605 aa). NFE2L2 acts in release from KEAP1 cysteine sensor -> nuclear binding to Antioxidant Response Elements (AREs) -> HMOX1, NQO1, GCLC/GCLM (glutathione), TXNRD1 & pentose phosphate NADPH, together with KEAP1 (Cytosolic Cysteine-Sensor Repressor & E3 Adaptor of NRF2), Glutathione (Synthesized by NRF2 Target Genes GCLC/GCLM), and Glucose-6-Phosphate Dehydrogenase (Induced by NRF2 for NADPH). Encodes NRF2 (NFE2L2), the master cap-n-collar bZIP transcription factor that activates cellular antioxidant, glutathione, and xenobiotic detoxification genes upon release from KEAP1.
Release from KEAP1 cysteine sensor -> nuclear binding to Antioxidant Response Elements (AREs) -> HMOX1, NQO1, GCLC/GCLM (glutathione), TXNRD1 & pentose phosphate NADPH
Clinical / Therapeutic Role
Master guardian against oxidative, electrophilic & ferroptotic stress; target of FDA-approved dimethyl fumarate (Tecfidera) for MS & omaveloxolone (Skyclarys) for Friedreich ataxia
Gene Structure & Expression
Genomic Organization & Cytogenetic Locus: 5-exon gene on chromosome 2q31.2 encoding a 605-amino-acid polypeptide composed of seven conserved Neh (NRF2-ECH homology) domains: Neh2 at the N-terminus contains the high-affinity ETGE and low-affinity DLG degron motifs that bind homodimeric KEAP1 (and where somatic cancer gain-of-function mutations cluster), Neh4/Neh5 recruit CBP/p300 coactivators, Neh6 contains a GSK-3beta/beta-TrCP phosphodegron, and Neh1 contains the CNC-bZIP DNA-binding domain that heterodimerizes with small Maf proteins (MAFF, MAFG, MAFK).
Cellular & Tissue Expression Profile: Ubiquitously transcribed in all human tissues, but under basal unstressed conditions the NRF2 protein has an ultra-short half-life of only ~15–20 minutes because cytosolic KEAP1 continuously presents it to the Cullin-3 (CUL3) E3 ubiquitin ligase for 26S proteasomal destruction.
Molecular Function & Pathways
Biochemical & Physiological Mechanism: When reactive oxygen species, lipid peroxidation products (4-HNE), or dietary/pharmacological electrophiles covalently modify reactive cysteine sensors (Cys151, Cys273, Cys288) on KEAP1, ubiquitination halts and newly synthesized NRF2 floods into the nucleus, heterodimerizes with small Maf proteins, and binds 5-prime-TGACNNNGC-3-prime Antioxidant Response Elements (AREs) across >250 cytoprotective genes: (1) glutathione synthesis and regeneration (GCLC, GCLM, GSR, SLC7A11 / xCT cystine importer that blocks ferroptosis); (2) thioredoxin/peroxiredoxin systems (TXN, TXNRD1, PRDX1); (3) heme and quinone detoxification (HMOX1 heme oxygenase-1, NQO1); (4) NADPH-generating enzymes (G6PD, PGD, ME1, IDH1); and (5) mitochondrial biogenesis via NRF1 induction.
Clinical & Therapeutic Significance
Human Genetic Variants & Disease Phenotypes: Comparative longevity studies show that naked mole-rats and long-lived bird/mammal species maintain constitutively elevated NFE2L2 signaling; in human oncology, somatic missense mutations in the NFE2L2 DLG/ETGE motifs (or loss-of-function mutations in KEAP1) occur in ~25–30% of lung squamous cell carcinomas and NSCLC, hijacking NRF2 antioxidant and metabolic protection to confer chemo- and radioresistance.
Therapeutic & Clinical Pharmacology: Clinically activated via KEAP1 Cys151 covalent modification by FDA-approved oral dimethyl fumarate (Tecfidera) and diroximel fumarate (Vumerity) for relapsing multiple sclerosis, by the synthetic oleanane triterpenoid omaveloxolone (Skyclarys, first FDA-approved therapy for Friedreich ataxia in 2023), and by dietary broccoli-sprout isothiocyanate sulforaphane.